Omnicell

OmniSphere Adoption Will Simplify Healthcare Medication Management

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

27 May 25

Updated

20 Nov 25

n/a

AnalystConsensusTarget's Fair Value

n/a

-18.6%

7.5%

-18.6%

7.5%

You can edit this narrative until Nov 21 1:10 AM. Then, changes will post as Updates.

Author's Valuation

US$47.3321.8% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates2

Shared on 20 Nov 25

OMCL: Share Repurchases And Executive Shifts Will Drive Future Upside

Analysts have revised their price target for Omnicell, lowering it modestly to $47.33 per share. This change reflects slight adjustments in key financial assumptions and uncertainty regarding future growth rates.

Shared on 06 Nov 25

Fair value Increased 7.58%

OMCL: Share Repurchases And Leadership Transition Will Strengthen Market Position

Omnicell's analyst price target has been raised from $44 to approximately $47.33 per share. Analysts cite improved outlooks for revenue growth, profit margins, and lower discount rates as reasons supporting the upward revision.

AnalystConsensusTarget Fair Value

US$47.33

21.8% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

3.83%

Medical Equipment revenue growth rate

7.75%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.99%

Calculation

US$51.57m

Earnings '28

45.20x

PE Ratio '28

US$2.33b

Market Cap '28

US$2.33b

Market Cap '28

39.67m

No. shares '28

US$58.76

Share Price '28

US$58.76 Share Price '28

Discounted to 2025 @ 8.09% p.a.

US$46.53

Fair Value '25